Ventripoint VMS™ Heart Analysis System Making Advances in Heart Disease Prognostics

Ventripoint Diagnostics Ltd. (TSXV:VPT) reported it completed two studies focusing on the utility of its VMS™ heart analysis system for right ventricle assessment in monitoring patients with congenital heart disease and pulmonary arterial hypertension. Both studies proved the utility of the VMS™ in determining if the therapy has been effective. Ventripoint has recently focused on marketing strategies, technology integration and further clinical studies to expand applications for the VMS.

As quoted in the press release:

Right heart function remains a significant prognostic parameter for all heart disease. The recent clearance has paved the way to further our product’s value by expanding its application to all major heart conditions. We have developed a regulatory strategy and although it is difficult to gauge timelines for FDA processes, we anticipate utilizing the Special 510(k) process using the VMS™ as the predicate device, and expect additional applications will be approved by the 3rd quarter this year.

Ventripoint Diagnostics CEO, Dr. George Adams, said:

The VMS™ is the first ultrasound system to be cleared as equivalent to MRI for right ventricle analysis. Now there is no need to wait to have an expensive MRI to functionally evaluate the right ventricle. We continue to build value for the Company by looking at all possible ways to market and advance the VMS™ with a focus on the upcoming cardiology meetings in the United States.

Click here to read the Ventripoint Diagnostics Ltd. (TSXV:VPT) press release